Moreover, clinical trials in patients with T-NHL have reported hyperprogression of individual T cell lymphomas, which were apparently still under PD-1 control, after anti-PD-1 treatment (NCT02631746 (refs. 5,6), NCT03075553 (ref. 7)). This evidence concerns the gene PDCD1 and non-Hodgkin lymphoma.